



ELSEVIER

Contents lists available at ScienceDirect

Data in Brief

journal homepage: www.elsevier.com/locate/dib

Data Article

Time-course gene expression data on the transcriptional effects of Aminaphtone on ECV304 endothelial cells



Giulia Salazar^a, Chiara Bellocchi^a, Katia Todoerti^b,
 Federica Saporiti^c, Luca Piacentini^c, Raffaella Scorza^a,
 Gualtiero I. Colombo^{c,*}

^a Referral Centre for Systemic Autoimmune Diseases, University of Milan and Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

^b Laboratory of Preclinical and Translational Research, IRCCS-CROB, Referral Cancer Centre of Basilicata, Rionero in Vulture, Italy

^c Laboratory of Immunology and Functional Genomics, Centro Cardiologico Monzino IRCCS, Milano, Italy

ARTICLE INFO

Article history:

Received 5 May 2016

Received in revised form

20 June 2016

Accepted 27 June 2016

Available online 2 July 2016

Chemical compound studied in this article:

Aminaphtone (PubChem CID: 84621)

Keywords:

Endothelial cells

Transcriptome

Inflammation

Vasoactive drug

ABSTRACT

We previously showed that Aminaphtone, a drug used in the treatment of chronic venous insufficiency, modulates several vasoactive factors, such as endothelin-1 and adhesion molecules. Here, we provide data of time-course experiments about the effects of Aminaphtone on gene expression at the genome-wide level in human endothelial cells undergoing cytokine stimulation *in vitro*. ECV-304 endothelial cells were incubated with interleukin-1 β (IL-1 β) in the presence or absence of Aminaphtone for 1, 3, and 6 h. Gene expression profiles were analyzed by microarray. This article contains complete data on the genes significantly modulated by the drug over time. The data are supplemental to our original research article reporting detailed analysis of the actions of Aminaphtone on IL-1 β stimulated endothelial cells at the molecular level, "Gene expression profiling reveals novel protective effects of Aminaphtone on ECV304 endothelial cells" (Salazar et al., 2016) [1].

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

DOI of original article: <http://dx.doi.org/10.1016/j.ejphar.2016.04.018>

* Corresponding author.

E-mail address: gualtiero.colombo@ccfm.it (G.I. Colombo).

<http://dx.doi.org/10.1016/j.dib.2016.06.051>

2352-3409/© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Specifications Table

Subject area	<i>Biology</i>
More specific subject area	<i>Cellular transcriptomics</i>
Type of data	<i>Tables, figure</i>
How data was acquired	<i>Affymetrix 7G Microarray Scanner (Affymetrix, Santa Clara, CA)</i>
Data format	<i>Filtered, analyzed</i>
Experimental factors	<i>Time-course experiments of gene expression responses of confluent human ECV304 endothelial cells, stimulated with recombinant IL-1β (100 IU/ml), to treatment with Aminaphtone (6 μg/ml) vs. medium alone</i>
Experimental features	<i>Whole-genome gene expression analysis performed at 1, 3, and 6-h time points using GeneChip Gene 1.0 ST Arrays (Affymetrix, Santa Clara, CA)</i>
Data source location	<i>Milan, Italy</i>
Data accessibility	<i>Filtered, analyzed data are reported within this article. Raw and normalized data are available via NCBI's GEO accession number GEO: GSE83297 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83297).</i>

Value of the data

- Previously unreported transcriptional effects of Aminaphtone, a drug currently used for the treatment of chronic venous insufficiency.
- Illustrate gene expression changes induced by Aminaphtone in a human endothelial cell line subjected to inflammatory stimulus.
- May facilitate further experiments to unveil the still unknown mechanism of action of this drug.
- May serve as a benchmark for comparison with data obtained in primary cells for further insight.
- May stimulate further research on the clinical use of this drug in other disease conditions, in which inflammation and endothelial dysfunction are key pathophysiological elements.

1. Data

Transcriptional effects of Aminaphtone treatment on human ECV304 endothelial cells stimulated with IL-1 β for 1, 3 and 6 h are shown in Table 1. The complete raw and normalized data are deposited in NCBI's Gene Expression Omnibus [2] and are accessible through GEO Series accession number GEO: GSE83297 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83297>). A hierarchically clustered heatmap of the differentially expressed genes (Fig. 1) visualizes the arrangement of treatment groups into clusters. Table 2 illustrates data on the functional enrichment analysis of modulated genes, showing gene sets and molecular pathways affected by Aminaphtone in IL-1 β stimulated ECV304 cells.

2. Experimental design, materials and methods

2.1. Cell cultures and treatments

Human ECV304 endothelial cells (European Collection of Authenticated Cell Cultures, ECACC No. 92091712) were seeded at $\times 10^5$ /well in 6-well tissue-culture treated plates and grown to confluence

Table 1
Differentially expressed genes in Aminaphtone-treated vs. untreated IL-1 β -stimulated ECV304 endothelial cells.

Symbol	Gene name	Gene ID	FDR	$P_{treatment}$	$P_{interaction}$	FC AMNA/IL-1 β			Pairwise		
						FC 1 h	FC 3 h	FC 6 h	1 h	3 h	6 h
<i>AAK1</i>	AP2 associated kinase 1	22848	9.13e-02	5.98e-03	7.26e-01	1.55	1.66	1.31			
<i>ACAP1</i>	ArfGAP with coiled-coil, ankyrin repeat and PH domains 1	9744	1.65e-02	2.07e-04	4.01e-01	-1.50	-1.23	-1.36	**		*
<i>AGAP2</i>	ArfGAP with GTPase domain, ankyrin repeat and PH domain 2	116986	1.73e-03	8.86e-05	4.53e-01	-1.39	-1.58	-1.31			**
<i>AK4</i>	adenylate kinase 4	205	8.79e-03	4.27e-01	7.56e-04	1.41	-1.01	-1.64	*		**
<i>ANKRD1</i>	ankyrin repeat domain 1 (cardiac muscle)	27063	8.02e-03	2.75e-02	1.23e-02	1.26	-1.46	-1.78			**
<i>ANKRD13A</i>	ankyrin repeat domain 13A	88455	8.98e-02	2.37e-04	1.88e-01	1.23	1.47	1.18			**
<i>ANXA3</i>	annexin A3	306	4.39e-04	7.76e-02	7.05e-04	1.48	-1.33	-1.70	**		**
<i>AREG</i>	amphiregulin	374	7.88e-02	6.01e-03	6.32e-01	-1.37	-1.39	-1.78			**
<i>ARHGEF26</i>	Rho guanine nucleotide exchange factor (GEF) 26	26084	7.10e-02	1.36e-03	9.35e-01	1.42	1.33	1.42			**
<i>ARL4C</i>	ADP-ribosylation factor-like 4C	10123	2.31e-02	2.22e-04	8.41e-01	-1.41	-1.30	-1.39	**		**
<i>ATF7IP2</i>	activating transcription factor 7 interacting protein 2	80063	5.87e-02	5.59e-03	1.69e-01	1.77	1.17	1.22	**		**
<i>BCL2L11</i>	BCL2-like 11 (apoptosis facilitator)	10018	8.59e-04	7.06e-05	3.23e-02	1.60	1.48	1.09	**	**	*
<i>BCL3</i>	B-cell CLL/lymphoma 3	602	4.12e-03	3.18e-02	5.00e-03	-1.98	-1.05	1.13			**
<i>BMP6</i>	bone morphogenetic protein 6	654	1.78e-02	3.25e-03	6.12e-02	-1.00	1.65	1.47		**	**
<i>BNIP3</i>	BCL2/adenovirus E1B 19 kDa interacting protein 3	664	0.00e+00	3.64e-05	4.09e-06	1.11	-1.12	-2.54			**
<i>BRCA1</i>	breast cancer 1, early onset	672	7.46e-02	4.42e-01	1.64e-02	1.96	-1.28	-1.15	**		**
<i>BUB1</i>	BUB1 mitotic checkpoint serine/threonine kinase	699	1.40e-02	5.76e-01	5.38e-03	1.93	-1.28	-1.26	**		**
<i>BUB1B</i>	BUB1 mitotic checkpoint serine/threonine kinase B	701	5.11e-02	4.12e-01	1.69e-02	2.09	-1.32	-1.14	**		**
<i>C14orf105</i>	chromosome 14 open reading frame 105	55195	6.13e-02	4.75e-03	5.28e-01	-1.22	-1.59	-1.62		*	*
<i>C15orf48</i>	chromosome 15 open reading frame 48	84419	5.83e-03	7.16e-05	4.51e-02	-1.61	-1.17	-1.25	**		**
<i>C1orf63</i>	chromosome 1 open reading frame 63	57035	3.07e-03	1.82e-04	3.43e-01	1.61	1.27	1.38	**		**
<i>C2orf44</i>	chromosome 2 open reading frame 44	80304	9.87e-03	1.63e-03	2.02e-01	1.79	1.35	1.20	**		**
<i>C3orf58</i>	chromosome 3 open reading frame 58	205428	1.08e-05	3.22e-01	1.35e-06	1.54	1.17	-1.61	**		**
<i>C7orf53</i>	chromosome 7 open reading frame 53	286006	6.37e-05	1.06e-03	1.05e-02	2.19	1.05	1.27	**		**
<i>C9orf131</i>	chromosome 9 open reading frame 131	138724	9.82e-03	4.39e-04	7.67e-02	1.67	1.21	1.19	**		**
<i>CACHD1</i>	cache domain containing 1	57685	4.66e-02	2.02e-03	4.84e-01	1.31	1.63	1.29		**	**
<i>CBLB</i>	Cbl proto-oncogene, E3 ubiquitin protein ligase B	868	8.71e-02	1.29e-02	2.19e-01	1.07	1.86	1.45		**	**
<i>CCL22</i>	chemokine (C-C motif) ligand 22	6367	0.00e+00	6.98e-06	6.53e-02	-1.36	-2.20	-1.99		**	**
<i>CD70</i>	CD70 molecule	970	9.39e-02	1.09e-03	2.37e-01	-1.53	-1.22	-1.20	**		**
<i>CD83</i>	CD83 molecule	9308	1.63e-03	4.10e-04	8.35e-02	1.80	1.22	1.27	**		**
<i>CEBPD</i>	CCAAT/enhancer binding protein (C/EBP), delta	1052	6.06e-03	4.58e-01	6.34e-04	-1.70	1.12	1.31	**		*
<i>CENPF</i>	centromere protein F, 350/400 kDa	1063	8.68e-02	6.92e-01	2.45e-02	1.90	-1.75	-1.31	*		**
<i>CEP55</i>	centrosomal protein 55 kDa	55165	4.42e-02	7.14e-01	8.10e-03	1.68	-1.40	-1.35	**		**
<i>CEP76</i>	centrosomal protein 76 kDa	79959	7.67e-02	2.29e-03	1.52e-01	1.57	1.32	1.09	**		**
<i>CHCHD7</i>	coiled-coil-helix-coiled-coil-helix domain containing 7	79145	6.62e-02	3.19e-03	4.05e-01	1.58	1.47	1.17	*		**
<i>CITED2</i>	Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2	10370	7.93e-02	2.38e-01	3.69e-03	-1.38	1.47	1.22		**	**

CKAP2L	cytoskeleton associated protein 2-like	150468	1.53e-02	1.45e-01	1.89e-02	1.57	-1.97	-1.57	.
CLEC4E	C-type lectin domain family 4, member E	26253	4.03e-03	8.42e-04	3.66e-01	-1.25	-1.53	-1.71	**
CNNM4	cyclin M4	26504	1.79e-07	9.46e-05	4.77e-04	-1.11	2.00	1.57	**
CSF2	colony stimulating factor 2 (granulocyte-macrophage)	1437	1.02e-03	8.79e-04	7.21e-01	-1.68	-1.88	-1.48	.
CTH	cystathionase (cystathionine gamma-lyase)	1491	6.66e-03	1.90e-04	3.46e-01	1.29	1.59	1.31	.
CTSK	cathepsin K	1513	2.91e-03	4.28e-04	9.47e-01	1.54	1.53	1.45	.
CUZD1	CUB and zona pellucida-like domains 1	50624	7.05e-02	3.72e-02	4.52e-02	1.95	1.02	1.05	**
CX3CL1	chemokine (C-X3-C motif) ligand 1	6376	1.25e-02	3.11e-03	4.58e-01	-1.94	-1.48	-1.33	.
CXCL3	chemokine (C-X-C motif) ligand 3	2921	8.34e-02	1.65e-02	5.71e-02	-1.70	-1.34	1.07	**
CXCL6	chemokine (C-X-C motif) ligand 6	6372	2.85e-03	1.69e-04	6.11e-01	-1.39	-1.34	-1.58	**
CYB5D1	cytochrome b5 domain containing 1	124637	2.40e-03	1.21e-03	7.39e-02	1.78	1.50	1.07	.
CYP24A1	cytochrome P450, family 24, subfamily A, polypeptide 1	1591	2.62e-05	4.54e-05	7.89e-01	-1.52	-1.69	-1.51	**
DBR1	debranching enzyme homolog 1 (<i>Saccharomyces cerevisiae</i>)	51163	7.97e-02	1.06e-03	4.21e-01	1.52	1.26	1.24	**
DDIT4	DNA-damage-inducible transcript 4	54541	5.57e-04	5.87e-04	5.05e-01	-1.90	-1.40	-1.57	**
DDR1	discoidin domain receptor tyrosine kinase 1	780	1.43e-02	1.48e-03	8.30e-02	-1.73	-1.26	-1.13	.
DENND2C	DENN/MADD domain containing 2C	163259	3.14e-02	1.33e-03	9.57e-01	1.44	1.49	1.40	.
DEPDC1	DEP domain containing 1	55635	5.44e-02	9.05e-01	1.02e-02	1.75	-1.26	-1.44	.
DKK1	dickkopf 1 homolog (<i>Xenopus laevis</i>)	22943	2.94e-05	5.83e-05	1.71e-02	-1.25	-1.25	-1.94	.
DLEU1	deleted in lymphocytic leukemia 1 (non-protein coding)	10301	7.23e-02	5.02e-03	1.27e-01	1.71	1.19	1.14	**
DLGAP5	discs, large (Drosophila) homolog-associated protein 5	9787	4.29e-03	1.58e-01	2.80e-03	1.51	-1.58	-1.42	.
DNAJB1	DnaJ (Hsp40) homolog, subfamily B, member 1	3337	1.36e-02	4.99e-03	4.35e-02	1.82	1.31	1.00	**
DUSP8	dual specificity phosphatase 8	1850	5.16e-03	1.05e-02	4.26e-03	-1.87	1.06	-1.07	.
EBI3	Epstein-Barr virus induced 3	10148	0.00e+00	6.30e-06	6.87e-01	-1.82	-1.73	-2.06	**
ECT2	epithelial cell transforming sequence 2 oncogene	1894	6.84e-03	5.43e-02	1.07e-02	1.36	-1.84	-1.45	**
EDN1	endothelin 1	1906	0.00e+00	2.33e-06	8.60e-01	-1.79	-1.93	-1.97	.
EFNA1	ephrin-A1	1942	4.91e-03	1.20e-03	2.03e-02	-1.74	-1.02	-1.31	.
EFNB2	ephrin-B2	1948	1.76e-02	3.27e-03	1.81e-01	1.81	1.40	1.13	**
EGR2	early growth response 2	1959	7.52e-03	3.57e-03	6.43e-03	-1.80	-1.04	-1.06	**
EIF4B	eukaryotic translation initiation factor 4B	1975	3.63e-02	4.03e-01	9.48e-03	1.56	-1.22	-1.69	.
EIF4EBP2	eukaryotic translation initiation factor 4E binding protein 2	1979	3.09e-04	5.53e-06	1.55e-01	1.25	1.56	1.42	.
ELF3	E74-like factor 3 (ets domain transcription factor, epithelial-specific)	1999	6.05e-02	3.62e-02	8.45e-03	-1.24	1.43	1.43	.
ELMSAN1	ELM2 and Myb/SANT-like domain containing 1	91748	3.96e-05	1.34e-02	1.00e-05	-1.86	1.19	1.08	**
ELOVL4	ELOVL fatty acid elongase 4	6785	8.64e-03	5.29e-04	3.98e-01	1.40	1.62	1.25	**
ELOVL6	ELOVL fatty acid elongase 6	79071	7.35e-02	1.86e-01	1.29e-02	1.84	-1.08	-1.15	.
ENO2	enolase 2 (gamma, neuronal)	2026	6.53e-05	1.50e-03	1.22e-02	-1.27	-1.06	-2.31	**
ERCC6L	excision repair cross-complementing rodent repair deficiency, complementation group 6-like	54821	6.72e-02	8.17e-01	1.39e-02	1.75	-1.58	-1.21	.
ERF	Ets2 repressor factor	2077	1.91e-02	4.84e-04	1.05e-01	-1.62	-1.22	-1.19	**
EVA1A	eva-1 homolog A (<i>Caenorhabditis elegans</i>)	84141	1.25e-06	3.14e-07	4.49e-03	-1.19	-1.47	-1.74	.
FAM102A	family with sequence similarity 102, member A	399665	3.29e-02	6.69e-02	5.48e-03	-1.32	1.41	1.48	.
FAM111B	family with sequence similarity 111, member B	374393	7.05e-02	5.89e-01	2.31e-02	2.18	-1.58	-1.06	.
FAM46C	family with sequence similarity 46, member C	54855	5.99e-04	5.82e-04	4.90e-03	1.87	1.20	1.03	**
FAM72D	family with sequence similarity 72, member D	728833	2.54e-04	4.65e-01	1.25e-03	1.86	-1.60	-1.46	.
FBLIM1	filamin binding LIM protein 1	54751	1.21e-03	1.31e-04	5.98e-01	-1.61	-1.38	-1.39	**

Table 1 (continued)

Symbol	Gene name	Gene ID	FDR	$P_{\text{treatment}}$	$P_{\text{interaction}}$	FC AMNA/IL-1 β			Pairwise		
						FC 1 h	FC 3 h	FC 6 h	1 h	3 h	6 h
FBXL20	F-box and leucine-rich repeat protein 20	84961	1.87e-04	2.46e-04	6.47e-02	1.19	1.91	1.40		**	*
FBXO33	F-box protein 33	254170	4.21e-02	9.72e-04	7.70e-02	1.22	1.62	1.13		**	
FLJ36840	uncharacterized LOC645524	645524	2.12e-02	1.52e-01	2.64e-02	2.66	-1.34	1.09		**	
FOS	FBJ murine osteosarcoma viral oncogene homolog	2353	4.65e-06	4.26e-04	3.84e-04	2.13	1.01	1.08		**	
FRMD6	FERM domain containing 6	122786	4.02e-02	1.16e-02	3.29e-02	1.11	-1.49	-1.57		**	**
FRMD8	FERM domain containing 8	83786	3.02e-02	6.15e-03	2.25e-02	-1.72	-1.23	1.03		**	
FST	follicistatin	10468	7.49e-02	1.12e-03	1.27e-01	-1.07	-1.44	-1.42		**	
FUT11	fucosyltransferase 11 (alpha (1,3) fucosyltransferase)	170384	5.23e-02	1.79e-03	6.02e-03	-1.14	1.00	-1.62		**	**
GAN	gigaxonin	8139	4.82e-02	6.57e-03	1.16e-01	1.80	1.22	1.12		**	
GAREM	GRB2 associated, regulator of MAPK1	64762	9.44e-02	1.61e-03	1.88e-02	-1.00	1.54	1.23		**	*
GAS2L3	growth arrest-specific 2 like 3	283431	5.77e-02	2.78e-01	1.30e-02	1.92	-1.14	-1.17		**	
GCLC	glutamate-cysteine ligase, catalytic subunit	2729	3.29e-02	2.08e-03	7.58e-01	1.56	1.53	1.32		**	
GCLM	glutamate-cysteine ligase, modifier subunit	2730	1.37e-02	1.51e-03	5.69e-01	1.71	1.40	1.35		**	
GLCC11	glucocorticoid induced transcript 1	113263	2.69e-02	1.03e-04	8.16e-01	1.37	1.38	1.28		**	
GPR56	G protein-coupled receptor 56	9289	1.49e-02	3.94e-03	7.47e-02	-1.85	-1.09	-1.27		**	
GPR89A	G protein-coupled receptor 89A	653519	5.78e-02	3.12e-03	3.52e-01	1.67	1.32	1.22		**	
GRB7	growth factor receptor-bound protein 7	2886	1.09e-02	1.07e-03	5.88e-02	-1.74	-1.18	-1.18		**	
GTF2B	general transcription factor IIB	2959	6.15e-04	8.75e-05	1.99e-01	1.69	1.35	1.29		**	*
HCAR1	hydroxycarboxylic acid receptor 1	27198	9.99e-02	3.02e-03	7.95e-01	-1.29	-1.45	-1.49		**	
HILPDA	hypoxia inducible lipid droplet-associated	29923	7.25e-05	9.73e-04	3.21e-03	-1.20	-1.01	-2.09		**	**
HIST1H2AK	histone cluster 1, H2ak	8330	3.09e-03	2.95e-03	1.11e-01	-1.05	-1.71	-1.85		**	**
HIST2H2BF	histone cluster 2, H2bf	440689	4.80e-03	4.43e-05	6.62e-01	1.36	1.32	1.47		**	**
HIST2H4A	histone cluster 2, H4a	8370	0.00e+00	4.91e-07	1.85e-02	1.87	1.46	1.32		**	**
HK2	hexokinase 2	3099	1.25e-06	4.59e-04	1.65e-03	1.06	-1.37	-2.25		**	**
HMMR	hyaluronan-mediated motility receptor (RHAMM)	3161	1.23e-02	2.21e-01	8.49e-03	1.58	-1.43	-1.71		**	**
HMOX1	heme oxygenase (decycling) 1	3162	1.69e-02	3.20e-04	3.02e-01	-1.51	-1.19	-1.41		**	**
ID2	inhibitor of DNA binding 2, dominant negative helix-loop-helix protein	3398	5.45e-03	1.51e-04	1.15e-02	1.38	1.58	1.03		**	**
IDI1	isopentenyl-diphosphate delta isomerase 1	3422	6.89e-02	4.10e-03	2.47e-01	1.70	1.21	1.23		**	**
IGFL1	IGF-like family member 1	374918	0.00e+00	1.06e-05	8.05e-01	-2.11	-2.05	-2.41		**	**
IL1B	interleukin 1, beta	3553	2.12e-03	1.50e-03	3.88e-01	-1.29	-1.92	-1.69		**	**
IL32	interleukin 32	9235	3.56e-03	8.70e-05	1.94e-01	-1.23	-1.34	-1.59		**	**
IL7R	interleukin 7 receptor	3575	2.09e-04	7.60e-04	8.60e-02	-1.11	-1.95	-1.69		**	**
IRF2BP2	interferon regulatory factor 2 binding protein 2	359948	1.26e-02	7.17e-02	2.00e-04	-1.65	1.11	1.13		**	*
ISCA1	iron-sulfur cluster assembly 1 homolog (<i>S. cerevisiae</i>)	81689	2.42e-02	2.41e-03	1.97e-01	1.60	1.54	1.10		**	*
ISG20L2	interferon stimulated exonuclease gene 20 kDa-like 2	81875	8.45e-02	4.01e-02	2.40e-03	-1.62	1.08	1.03		**	**
KCTD11	potassium channel tetramerisation domain containing 11	147040	4.26e-05	1.92e-04	3.55e-01	-1.91	-1.36	-1.65		**	**
KDEL1C	KDEL (Lys-Asp-Glu-Leu) containing 1	79070	5.23e-02	7.58e-05	3.32e-01	1.20	1.43	1.30		**	**
KHDRBS3	KH domain containing, RNA binding, signal transduction associated 3	10656	1.79e-03	2.61e-06	7.74e-04	1.05	1.57	1.32		**	**

KIAA0922	KIAA0922	23240	1.60e-02	1.12e-03	3.47e-01	1.25	1.68	1.35	
KIAA1524	KIAA1524	57650	2.09e-02	3.06e-01	1.10e-02	1.64	-1.68	-1.44	
KIF14	kinesin family member 14	9928	1.42e-02	8.55e-01	1.29e-02	2.46	-1.70	-1.31	
KIF23	kinesin family member 23	9493	7.31e-02	1.00e+00	1.64e-02	1.88	-1.46	-1.29	
KLRAP1	killer cell lectin-like receptor subfamily A pseudogene 1	10748	9.99e-02	9.35e-01	2.08e-02	1.86	-1.58	-1.22	
KRT16	keratin 16	3868	8.89e-04	7.06e-04	5.60e-01	-1.73	-1.76	-1.37	
KRT17	keratin 17	3872	1.35e-03	6.95e-04	2.03e-01	-1.86	-1.24	-1.43	
KRT34	keratin 34	3885	6.82e-02	5.18e-04	8.08e-01	-1.27	-1.37	-1.40	
LAMB3	laminin, beta 3	3914	9.31e-03	7.05e-04	8.37e-01	-1.57	-1.44	-1.39	
LIF	leukemia inhibitory factor	3976	1.04e-03	1.87e-02	1.93e-03	-1.34	1.51	1.62	
LMCD1	LIM and cysteine-rich domains 1	29995	7.13e-02	2.87e-04	8.53e-01	-1.38	-1.33	-1.28	
LOC100130713	uncharacterized LOC100130713	100130713	8.73e-03	3.78e-02	1.06e-03	-1.33	1.51	1.34	
LOC440896	uncharacterized LOC440896	440896	1.04e-02	7.89e-04	8.40e-01	-1.55	-1.49	-1.37	
LOX	lysyl oxidase	4015	2.52e-02	2.34e-04	3.94e-02	-1.15	-1.19	-1.60	
LPIN1	lipin 1	23175	1.40e-03	2.40e-04	4.71e-02	1.72	1.37	1.12	
MARCH8	membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase	220972	7.20e-02	2.41e-03	2.60e-01	1.12	1.54	1.42	
MEF2D	myocyte enhancer factor 2D	4209	4.21e-03	9.11e-02	1.55e-03	-1.84	1.24	-1.00	
MEGF9	multiple EGF-like-domains 9	1955	1.01e-04	2.69e-04	9.48e-01	1.62	1.76	1.69	
MERTK	c-mer proto-oncogene tyrosine kinase	10461	6.83e-05	2.96e-05	6.07e-02	1.28	1.79	1.32	
MINPP1	multiple inositol-polyphosphate phosphatase 1	9562	4.12e-02	2.07e-03	6.87e-01	1.51	1.54	1.28	
MIR29A	microRNA 29a	407021	6.91e-05	9.06e-04	3.57e-01	1.59	1.74	2.69	
MKI67	antigen identified by monoclonal antibody Ki-67	4288	2.28e-02	6.57e-01	1.27e-02	2.18	-1.58	-1.13	
MMP1	matrix metalloproteinase 1 (interstitial collagenase)	4312	1.40e-04	1.11e-03	3.61e-02	-1.08	-1.44	-2.18	
MMP10	matrix metalloproteinase 10 (stromelysin 2)	4319	5.96e-08	1.29e-04	1.54e-03	-1.02	-1.38	-2.37	
MMP3	matrix metalloproteinase 3 (stromelysin 1, progelatinase)	4314	1.93e-05	1.63e-03	2.51e-02	-1.01	-1.63	-2.57	
MOB3C	MOB kinase activator 3C	148932	2.40e-02	1.54e-02	7.70e-03	-1.78	1.01	-1.02	
MYLIP	myosin regulatory light chain interacting protein	29116	0.00e+00	9.67e-07	8.89e-05	2.84	1.52	1.12	
NAV3	neuron navigator 3	89795	7.05e-02	6.46e-01	6.03e-03	1.55	-1.42	-1.24	
NCAPG	non-SMC condensin I complex, subunit G	64151	8.61e-02	7.39e-01	1.66e-02	1.89	-1.41	-1.18	
NEK2	NIMA-related kinase 2	4751	5.47e-02	2.39e-01	7.63e-03	1.78	-1.23	-1.04	
NINJ1	ninjurin 1	4814	6.07e-02	5.10e-03	8.39e-02	-1.70	-1.25	-1.06	
NIPAL4	NIPA-like domain containing 4	348938	4.83e-03	6.92e-04	3.07e-01	-1.74	-1.31	-1.32	
NR4A2	nuclear receptor subfamily 4, group A, member 2	4929	2.09e-03	5.30e-01	1.08e-03	-1.85	1.21	1.31	
NUAK2	NUAK family, SNF1-like kinase, 2	81788	1.41e-02	3.76e-04	1.70e-01	-1.60	-1.19	-1.30	
NXF1	nuclear RNA export factor 1	10482	1.95e-02	4.17e-04	7.68e-02	1.19	1.63	1.20	
OLFM2	olfactomedin 2	93145	9.51e-02	4.42e-03	7.98e-02	-1.65	-1.13	-1.14	
OSBPL11	oxysterol binding protein-like 11	114885	9.51e-02	8.43e-03	4.90e-01	1.84	1.30	1.37	
OXTR	oxytocin receptor	5021	1.11e-03	9.51e-06	5.52e-03	-1.10	-1.62	-1.32	
P4HA1	prolyl 4-hydroxylase, alpha polypeptide 1	5033	1.04e-04	4.09e-01	3.61e-04	1.58	-1.02	-1.89	
PCF11	PCF11, cleavage and polyadenylation factor subunit, homolog (<i>S. cerevisiae</i>)	51585	2.42e-02	3.67e-02	3.25e-02	2.13	-1.01	1.06	
PDGFB	platelet-derived growth factor beta polypeptide	5155	2.00e-04	6.09e-04	9.34e-02	-2.09	-1.26	-1.36	
PDK1	pyruvate dehydrogenase kinase, isozyme 1	5163	1.91e-06	2.69e-02	4.56e-04	1.44	-1.19	-2.37	
PDZK1IP1	PDZK1 interacting protein 1	10158	3.32e-02	2.18e-03	6.99e-02	-1.60	-1.03	-1.39	
PER1	period circadian clock 1	5187	1.43e-02	6.69e-02	3.66e-03	-1.84	1.08	1.08	

Table 1 (continued)

Symbol	Gene name	Gene ID	FDR	$P_{\text{treatment}}$	$P_{\text{interaction}}$	FC AMNA/IL-1 β			Pairwise		
						FC 1 h	FC 3 h	FC 6 h	1 h	3 h	6 h
PFKFB4	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4	5210	0.00e+00	3.32e-04	6.63e-05	-1.06	1.04	-2.67			**
PHLDA3	pleckstrin homology-like domain, family A, member 3	23612	4.60e-02	7.89e-04	5.33e-01	-1.52	-1.27	-1.31	**		*
PIK3R1	phosphoinositide-3-kinase, regulatory subunit 1 (alpha)	5295	2.59e-03	1.84e-02	2.19e-02	2.40	1.14	-1.02	**		
PIK3R3	phosphoinositide-3-kinase, regulatory subunit 3 (gamma)	8503	1.86e-02	4.86e-04	5.59e-01	1.28	1.54	1.37		**	*
PLAT	plasminogen activator, tissue	5327	3.74e-02	1.90e-02	1.06e-01	-2.20	-1.18	-1.12	**		
PLCB4	phospholipase C, beta 4	5332	7.45e-06	3.68e-02	2.37e-03	1.73	-2.07	-2.14	*	**	**
PLEKHG2	pleckstrin homology domain containing, family G (with RhoGef domain) member 2	64857	3.71e-02	3.43e-03	7.01e-02	-1.72	-1.23	-1.08	**		
PLEKHM1	pleckstrin homology domain containing, family M (with RUN domain) member 1	9842	8.05e-02	9.03e-02	1.43e-02	-1.28	1.65	1.26		**	
PLEKHM3	pleckstrin homology domain containing, family M, member 3	389072	3.51e-02	4.36e-03	9.12e-01	1.57	1.78	1.56		*	
PODXL	podocalyxin-like	5420	1.55e-02	8.88e-04	9.91e-03	-1.05	-1.16	-1.69		**	
POLA1	polymerase (DNA directed), alpha 1, catalytic subunit	5422	9.69e-02	3.40e-01	2.19e-02	1.95	-1.35	-1.00	**		
PPP1R18	protein phosphatase 1, regulatory subunit 18	170954	2.09e-02	7.61e-03	1.02e-02	-1.77	-1.06	-1.02	**		
PPP1R3C	protein phosphatase 1, regulatory subunit 3C	5507	1.19e-02	9.34e-03	7.03e-02	1.04	-1.54	-1.94	**		**
PRDM1	PR domain containing 1, with ZNF domain	639	0.00e+00	1.29e-05	3.46e-06	-2.47	-1.04	-1.01	**		
PRKCA	protein kinase C, alpha	5578	3.16e-03	6.04e-04	9.57e-01	1.48	1.59	1.54	**	**	*
PRSS22	protease, serine, 22	64063	2.23e-02	3.34e-04	8.39e-01	-1.41	-1.43	-1.31	**	**	
PTCH1	patched 1	5727	8.87e-02	1.19e-02	6.15e-03	-1.02	1.65	1.04	**	**	
PTP4A3	protein tyrosine phosphatase type IVA, member 3	11156	1.22e-04	2.90e-04	3.74e-01	-1.51	-1.95	-1.41	**	**	
PXDC1	PX domain containing 1	221749	3.90e-02	3.71e-01	2.02e-03	-1.66	1.16	1.19	**	*	
RAI14	retinoic acid induced 14	26064	9.76e-02	7.26e-01	1.68e-02	1.87	-1.31	-1.26	**	*	
RASD2	RASD family, member 2	23551	6.21e-02	7.34e-04	2.19e-02	-1.58	-1.08	-1.15	**		
RASSF5	Ras association (RalGDS/AF-6) domain family member 5	83593	9.60e-02	2.47e-04	6.95e-01	-1.29	-1.39	-1.25	**	**	
RIPK4	receptor-interacting serine-threonine kinase 4	54101	1.33e-03	3.07e-04	1.37e-02	-1.79	-1.10	-1.23	**		
RND1	Rho family GTPase 1	27289	9.23e-03	1.56e-02	5.23e-02	-1.12	1.59	2.06	**		
RNF103	ring finger protein 103	7844	6.68e-02	2.52e-03	9.20e-01	1.44	1.51	1.37	**	*	
RRM2	ribonucleotide reductase M2	6241	5.93e-02	3.12e-03	1.19e-02	1.59	1.22	-1.04	**	**	
S100A3	S100 calcium binding protein A3	6274	0.00e+00	7.47e-06	5.36e-02	-2.37	-1.37	-2.05	**	**	**
SAMD4A	sterile alpha motif domain containing 4A	23034	7.19e-04	4.28e-06	7.70e-02	1.22	1.56	1.36	*	**	**
SELE	selectin E	6401	2.45e-03	2.50e-03	1.08e-02	-1.01	1.24	1.89	**	*	**
SEMA4C	sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4C	54910	9.90e-02	1.27e-03	8.89e-02	-1.53	-1.26	-1.08	**	*	
SERPINA3	serpin peptidase inhibitor, clade A (alpha-1 antitrypsin, antitrypsin), member 3	12	2.93e-03	4.08e-03	1.68e-01	-2.38	-1.29	-1.37	**		
SERPINB9	serpin peptidase inhibitor, clade B (ovalbumin), member 9	5272	4.70e-02	4.96e-03	1.48e-01	-1.07	-1.39	-1.72			**
SERPINH1	serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)	871	6.23e-02	1.47e-03	4.28e-01	-1.27	-1.27	-1.58			**

Table 1 (continued)

Symbol	Gene name	Gene ID	FDR	$P_{\text{treatment}}$	$P_{\text{interaction}}$	FC AMNA/IL-1 β			Pairwise		
						FC 1 h	FC 3 h	FC 6 h	1 h	3 h	6 h
ULBP3	UL16 binding protein 3	79465	5.51e-02	3.20e-04	1.21e-01	1.30	1.50	1.12	*	**	
ULK1	unc-51-like kinase 1 (<i>C. elegans</i>)	8408	8.48e-02	4.11e-01	2.45e-03	-1.44	1.33	1.27	**	*	
USP38	ubiquitin specific peptidase 38	84640	8.54e-03	1.46e-04	4.15e-01	1.53	1.34	1.27	**	**	*
VAMP1	vesicle-associated membrane protein 1 (synaptobrevin 1)	6843	1.08e-03	3.77e-05	4.65e-01	1.49	1.48	1.28	**	**	*
VLDLR	very low density lipoprotein receptor	7436	4.04e-02	4.49e-04	2.18e-03	-1.05	-1.08	-1.61			**
ZC3H7B	zinc finger CCCH-type containing 7B	23264	6.99e-02	4.01e-04	8.97e-01	-1.39	-1.30	-1.32	**		
ZC3HAV1	zinc finger CCCH-type, antiviral 1	56829	4.54e-02	3.89e-03	2.25e-01	1.74	1.29	1.17	**		
ZCCHC14	zinc finger, CCHC domain containing 14	23174	3.05e-02	1.36e-03	9.05e-02	1.11	1.66	1.27		**	
ZNF253	zinc finger protein 253	56242	5.52e-02	2.43e-02	1.07e-01	2.18	1.16	1.11	**	*	
ZNF426	zinc finger protein 426	79088	6.98e-02	3.42e-03	7.62e-01	1.55	1.51	1.30	**	*	
ZNF48	zinc finger protein 48	197407	5.05e-02	5.04e-03	1.14e-02	-1.67	-1.07	-1.03	**		
ZNF487P	zinc finger protein 487, pseudogene	642819	5.33e-05	1.01e-03	5.62e-02	1.47	2.43	1.18	**	**	
ZNF724P	zinc finger protein 724, pseudogene	440519	3.69e-02	1.45e-01	1.73e-02	2.07	-1.05	-1.15	**		
ZNF737	zinc finger protein 737	100129842	2.08e-02	6.03e-03	3.48e-01	2.11	1.29	1.46	**		
ZSWIM6	zinc finger, SWIM-type containing 6	57688	4.63e-02	5.34e-03	4.44e-01	1.55	1.78	1.22		*	

P -values in bold if significant at two-factor ANOVA (< 0.05).

FDR: false discovery rate, according to BETR analysis. $P_{\text{treatment}}$: P -value for treatment effect; and $P_{\text{interaction}}$: P -value for interaction effect, at two-factor ANOVA. FC: fold-change in Aminaphthone-treated vs. untreated IL-1 β -stimulated endothelial cells. AMNA: Aminaphthone. Pairwise: pairwise significant at two-tailed t -test.

* $P < 0.05$.

** $P < 0.01$ at two-tailed t -test.




Fig. 1. Unsupervised hierarchical clustering of significant genes modulated over time by Aminaphtone in treated vs. untreated IL-1 β stimulated ECV304 endothelial cells. The BETR algorithm identified 252 significantly modulated genes (FDR < 0.1). Samples and genes were clustered using Pearson's correlation (centered) and average linkage method. Each combination of treatments and time points regrouped in distinct clusters. The log₂ transformed, normalized, median-centered expression level of each gene is represented with a blue, black, and orange color scale: blue indicates below median, black, equal to, and orange above median. Class legends stand for: IL-1 β (IL-1 β without Aminaphtone); AMNA (IL-1 β with Aminaphtone).

in M199 complete medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT), at 37 °C in a humidified incubator with 5% CO₂. Cells were serum starved (1% FBS) to synchronize the mitotic phase 24 h before treatment. Cells were then incubated for 1, 3, and 6 h with recombinant IL-1 β 100 IU/ml (Sigma-Aldrich, St. Louis, MO) in the presence of

Table 2
Gene sets significantly modulated by Aminaphtone in treated vs. untreated IL-1 β -stimulated endothelial cells.

GO Category ^a	GO Ontology	GO term	#genes	LS	KS	Gene list
0005975	BP	carbohydrate metabolic process	11	0.0805	0.0028	<i>DDIT4, ENO2, FUT11, GCLC, HK2, HMMR, PDGFB, PDK1, PFKFB4, PPP1R3C, SLC2A1</i>
0007166	BP	cell surface receptor signaling pathway	46	0.0260	0.0020	<i>AAK1, BCL2L11, BMP6, CBLB, CITED2, CX3CL1, DDIT4, DDR1, DKK1, EBI3, ECT2, EDN1, EFNA1, EFN2, EIF4B, EIF4EBP2, FOS, FST, GAREM, GPR56, GRB7, IL1B, IL7R, KCTD11, LIF, MERTK, OXTR, PDGFB, PIK3R1, PIK3R3, PLAT, PLEKHG2, PRDM1, PRKCA, PTCH1, SEMA4C, STAT5A, STC1, STC2, TGFB111, TGFB2, TICAM1, TLE1, TNFSF18, ULK1, VLDLR</i>
0022411	BP	cellular component disassembly	7	0.0042	0.8859	<i>BNIP3, DDIT4, DDR1, MMP1, MMP10, MMP3, TOP2A</i>
0048732	BP	gland development	11	0.0031	0.0022	<i>BCL2L11, CITED2, DDR1, ELF3, HK2, ID2, OXTR, PDGFB, PTCH1, STAT5A, TGFB2</i>
0042592	BP	homeostatic process	26	0.0015	0.2886	<i>BCL2L11, BNIP3, CITED2, CTSK, EDN1, EGR2, GCLC, GCLM, GPR89A, HK2, HMOX1, ID2, IL1B, IL7R, MYLIP, OXTR, POLA1, PRKCA, PTCH1, SERPINA3, STAT5A, STC1, STC2, TFRC, TGFB2, TNFRSF11B</i>
0002376	BP	immune system process	47	0.0015	0.0284	<i>ANXA3, BCL2L11, BCL3, BMP6, BNIP3, CBLB, CCL22, CD70, CD83, CITED2, CLEC4E, CSF2, CTSK, CX3CL1, CXCL3, CXCL6, DDIT4, EBI3, EDN1, FOS, FST, GRB7, HMOX1, ID2, IL1B, IL32, IL7R, KIF23, LIF, MARCH8, MERTK, MMP1, PDGFB, PIK3R1, PIK3R3, PODXL, PRDM1, PRKCA, SELE, SERPINB9, STAT5A, TFRC, TGFB2, TICAM1, TNFSF18, ULBP3, ZC3HAV1</i>
0006954	BP	inflammatory response	15	0.0131	0.0047	<i>BMP6, CCL22, CX3CL1, CXCL3, ELF3, FOS, HMOX1, IL1B, PRKCA, SELE, SERPINA3, STAT5A, TICAM1, TNFAIP6</i>
0043066	BP	negative regulation of apoptotic process	20	0.0028	0.0677	<i>AGAP2, BCL3, BNIP3, CITED2, CSF2, CTH, CX3CL1, EDN1, GCLC, GCLM, HMOX1, IL1B, NR4A2, NUA2, PIK3R1, PRKCA, SERPINB9, STAT5A, TLE1, TNFSF18</i>
0007389	BP	pattern specification process	6	0.0137	0.0006	<i>CITED2, DKK1, EDN1, EGR2, FST, PTCH1</i>
0010646	BP	regulation of cell communication	49	0.1744	0.0034	<i>AAK1, ACAP1, AGAP2, ANKRD1, ARHGEP26, BCL2L11, BCL3, BMP6, BNIP3, CBLB, CITED2, CSF2, CTH, DDIT4, DKK1, DUSP8, ECT2, EDN1, EFNA1, EGR2, FST, GAREM, GPR89A, HMOX1, IL1B, KCTD11, LIF, LMCD1, OXTR, PDGFB, PHLDA3, PLAT, PLEKHG2, PRDM1, PRKCA, PTCH1, RASD2, SEMA4C, SLC2A1, SPRY4, SYDE1, TGFB111, TGFB2, TICAM1, TLE1, TRAF1, TRIP6, ULK1, ZC3HAV1</i>
0042127	BP	regulation of cell proliferation	23	0.0019	0.0322	<i>BMP6, BRCA1, CBLB, CSF2, DDR1, EBI3, EDN1, GAREM, HILPDA, HMOX1, ID2, IL1B, KCTD11, LIF, PDGFB, PRDM1, PRKCA, PTCH1, STAT5A, TGFB111, TGFB2, TICAM1, TNFSF18</i>
0045619	BP	regulation of lymphocyte differentiation	5	0.0009	0.0034	<i>CD83, ID2, IL7R, PRDM1, STAT5A</i>
0051246	BP	regulation of protein metabolic process	38	0.0567	0.0032	<i>AGAP2, BCL3, BMP6, BRCA1, BUB1B, CBLB, CSF2, DDIT4, DKK1, DUSP8, EBI3, ECT2, EDN1, EFNA1, EIF4B, EIF4EBP2, GCLC, GRB7, HMOX1, IL1B, KRT17, LIF, LPIN1, MYLIP, PDGFB, PLAT, PRKCA, RASD2, SAMD4A, SERPINA3, SERPINB9, SERPINH1, SERPINI1, SPRY4, STAT5A, TGFB2, TICAM1, VLDLR</i>
0051090	BP	regulation of sequence-specific DNA binding transcription factor activity	10	0.0020	0.0058	<i>ANXA3, CTH, FOS, HMOX1, ID2, IL1B, PTCH1, TICAM1, TNFSF18, TRAF1</i>

0006357	BP	regulation of transcription from RNA polymerase II promoter	30	0.0035	0.6000	ANKRD1, BCL3, BMP6, BRCA1, CITED2, DKK1, EDN1, EFNA1, EGR2, ELF3, ERF, FOS, FST, HMOX1, ID2, IL1B, LIF, LMCD1, LPIN1, MEF2D, NR4A2, PER1, PIK3R1, POLA1, PRDM1, PTCH1, RRM2, STAT5A, TOP2A, VLDLR
0036293	BP	response to decreased oxygen levels	14	0.0024	0.0002	ANKRD1, BNIP3, CITED2, DDIT4, EDN1, HMOX1, NR4A2, OXTR, PDGFB, PDK1, PLAT, STC1, STC2, TGFB2
0009605	BP	response to external stimulus	32	0.0001	0.0071	AGAP2, ANKRD1, BNIP3, CCL22, CITED2, CX3CL1, CXCL3, CXCL6, CYP24A1, EDN1, EFN2, EGR2, ELOVL4, FOS, HMOX1, ID2, IL1B, NR4A2, NUA2, PDGFB, PER1, PLAT, PRKCA, RND1, SELE, SLC2A1, STAT5A, STC1, STC2, TGFB2, TNFRSF11B, ULK1
0010033	BP	response to organic substance	48	< 0.0001	0.0168	ANKRD1, BMP6, BRCA1, CD83, CITED2, CSF2, CTH, CX3CL1, CYP24A1, DKK1, DNAJB1, EBI3, EDN1, EGR2, EIF4B, EIF4EBP2, FOS, GAREM, GCLC, HCAR1, HMOX1, IDI1, IL1B, IL7R, LOX, LPIN1, MMP3, NR4A2, OXTR, PDGFB, PIK3R1, PIK3R3, PLAT, PRDM1, PRKCA, PTCH1, SELE, SERPINB9, SERPINH1, STAT5A, STC1, STC2, TGFB111, TGFB2, TICAM1, TNFRSF11B, TNFSF18, ZC3HAV1
0048511	BP	rhythmic process	6	0.0033	0.0194	EGR2, ID2, OXTR, PER1, STAT5A, TGFB2
0046903	BP	secretion	20	0.0238	0.0008	ANKRD1, ANXA3, BMP6, CLEC4E, DDR1, EDN1, FST, HK2, HMOX1, IL1B, LIF, MERTK, OXTR, PDGFB, PRKCA, SLC2A1, SRGN, STAT5A, TGFB2, VAMP1
0005125	MF	cytokine activity	15	0.0061	0.0047	BMP6, CCL22, CD70, CSF2, CX3CL1, CXCL3, CXCL6, EBI3, EDN1, IL1B, IL32, LIF, TGFB2, TNFRSF11B, TNFSF18
0004175	MF	endopeptidase activity	6	0.0004	0.1037	CTSK, MMP1, MMP10, MMP3, PLAT, PRSS22
0001071	MF	nucleic acid binding transcription factor activity	11	0.0006	0.0382	BCL3, CEBP2, CITED2, EGR2, ELF3, ERF, FOS, MEF2D, NR4A2, PRDM1, STAT5A
0000988	MF	protein binding transcription factor activity	11	0.0990	0.0032	ANKRD1, BRCA1, CITED2, ELF3, ERF, LIF, LMCD1, LPIN1, PER1, TGFB111, TLE1
0019904	MF	protein domain specific binding	5	0.0031	0.0167	ACAP1, CITED2, EGR2, IL1B, KHDRBS3
0001067	MF	regulatory region nucleic acid binding	6	0.0040	0.0378	BRCA1, EGR2, FOS, MEF2D, PER1, STAT5A
0031012	CC	extracellular matrix	9	0.0034	0.0040	LAMB3, LMCD1, LOX, MMP1, MMP10, MMP3, TGFB111, TGFB2, TNFRSF11B
0005615	CC	extracellular space	31	0.0003	< 0.0001	BMP6, CCL22, CD70, CSF2, CTSK, CX3CL1, CXCL3, CXCL6, DKK1, EBI3, EDN1, HILPDA, HMOX1, IGFL1, IL1B, IL32, LIF, LMCD1, LOX, MERTK, MMP10, MMP3, PLAT, SELE, SERPINB9, SRGN, STC1, TGFB2, TNFRSF11B, TNFSF18, VLDLR

KEGG Pathway ^b	Pathway description	#genes	LS	KS	Gene list
hsa04060	Cytokine–cytokine receptor interaction	13	0.0287	0.0095	CCL22, CD70, CSF2, CX3CL1, CXCL3, CXCL6, IL1B, IL7R, LIF, PDGFB, TGFB2, TNFRSF11B, TNFSF18
Broad MSigDB Curated Gene Set ^c		#genes	LS	KS	Gene list
HINATA_NFKB_TARGETS KERATINOCYTE_UP		13	0.0004	0.0095	CD83, CSF2, CXCL3, CXCL6, EFNA1, IL1B, IL32, IL7R, MMP1, PLAT, STAT5A, TNFAIP6, TRAF1
HINATA_NFKB_TARGETS FIBROBLAST_UP		6	0.0027	0.1123	CD83, CXCL3, CXCL6, IL1B, MMP1, SELE
SCHOEN_NFKB_SIGNALING		5	0.0192	0.0036	CSF2, EDN1, IL1B, NUA2, SERPINA3
ELVIDGE_HYPOXIA_UP		19	0.0017	0.0010	AK4, BNIP3, CITED2, DDIT4, DDR1, ELF3, ENO2, FOS, HK2, LOX, P4HA1, PDGFB, PDK1, PRKCA, SAMD4A, SLC2A1, STC1, STC2, VLDLR
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN		14	0.0036	0.0001	AK4, BNIP3, CITED2, ENO2, FOS, HK2, LOX, P4HA1, PDGFB, PDK1, SAMD4A, SLC2A1, STC1, VLDLR
ELVIDGE_HYPOXIA_BY_DMOG_UP		17	0.0038	0.0023	

Table 2 (continued)

Broad MSigDB Curated Gene Set ^c	#genes	LS	KS	Gene list
				AK4, BNIP3, CITED2, DDIT4, ELF3, ENO2, FOS, HK2, LOX, P4HA1, PDK1, PRKCA, SAMD4A, SLC2A1, STC1, STC2, VLDLR
ELVIDGE_HIF1A_TARGETS_DN	13	0.0114	0.0002	AK4, BNIP3, CITED2, ENO2, FOS, HK2, LOX, P4HA1, PDGFB, PDK1, SLC2A1, STC1, VLDLR
WINTER_HYPOXIA_METAGENE	18	0.0022	0.0376	BNIP3, CITED2, DDIT4, EDN1, EFNA1, ELF3, FOS, HK2, HMOX1, ID2, LOX, P4HA1, PDGFB, PFKFB4, SLC2A1, SLC6A8, STC2, TFRC
PID_HIF1_TFPATHWAY	9	0.0022	0.2078	BNIP3, CITED2, EDN1, FOS, HK2, HMOX1, ID2, SLC2A1, TFRC
MENSE_HYPOXIA_UP	10	0.0028	0.0004	BNIP3, CEBPD, ENO2, HK2, LOX, P4HA1, PDK1, PFKFB4, PPP1R3C, STC2
LEONARD_HYPOXIA	11	0.0061	0.0007	AK4, BNIP3, DDIT4, EFNA1, HK2, P4HA1, PDGFB, PFKFB4, PPP1R3C, SLC2A1, STC2
JIANG_HYPOXIA_NORMAL	15	0.0134	0.0009	AK4, BNIP3, CITED2, CNNM4, EIF4B, ENO2, HMOX1, KHDRBS3, LOX, P4HA1, PFKFB4, PPP1R3C, RIPK4, SLC2A1, STC2
KRIEG_HYPOXIA_VIA_KDM3A	5	0.0182	0.0026	C15orf48, CLEC4E, EDN1, HMOX1, LAMB3
FARDIN_HYPOXIA_11	6	0.0200	0.0029	AK4, BNIP3, DDIT4, FUT11, PDK1, PFKFB4
NAGASHIMA_EGF_SIGNALING_UP	8	0.0008	0.0007	AREG, DNABJ1, EDN1, EGR2, FOS, LIF, NR4A2, TNFRSF11B
ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP	22	0.0021	0.0070	BCL3, C15orf48, CD83, CXCL3, DDIT4, EDN1, EFNA1, GCLC, IGFL1, IL1B, IL32, IL7R, LAMB3, LIF, MMP10, NAV3, NINJ1, SAMD4A, SEMA4C, SERPINB9, TNFAIP6, TRAF1
BASSO_CD40_SIGNALING_UP	8	0.00498	0.0093	CCL22, CD83, DDIT4, IL1B, PTP4A3, SRGN, STAT5A, TRAF1
WIERENGA_STAT5A_TARGETS_GROUP2	5	0.0163	0.0036	CCL22, CD83, CSF2, IL7R, TRAF1

GO ontology: BP=biological process, MF=molecular function, and CC=cellular component.

^a GO (Gene Ontology) categories,

^b KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways, and

^c MSigDB (Broad Institute Molecular Signature Database) curated gene sets found to be significant at the 0.005 significance level of either the LS or KS permutation tests. For each Gene Set, the table lists the unique identifier, the number of genes differentially modulated, the Fisher (LS) and Kolmogorov–Smirnov (KS) permutation *P*-values (*P*-values < 0.005 are in bold), and the list of modulated genes.

Aminaphtone 6 µg/ml (Baldacci, Pisa, Italy) or an equal volume of medium alone. Experiments were performed in three independent replicates for each time point.

2.2. RNA isolation and whole-genome gene expression profiling

Total RNA extraction was performed with TRIzol (Life Technologies, Rockville, MD) directly added to the ECV304 culture plates. Removal of contaminating genomic DNA was done by treating RNA samples with RNase-free Turbo DNase (Life Technologies) for 15 min at room temperature. RNA quantity and quality were assessed respectively by micro-volume spectrophotometry on an Infinite 200 PRO plate reader (Tecan, Männedorf, Switzerland) and by on-chip capillary electrophoresis on a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). Absorbance ratio at 260 and 280 nm was ≥ 1.9 and the RNA integrity number (RIN) was > 8 for all samples.

For each replicate, 100 ng of total RNA were amplified and labeled using the Whole-Transcript Sense Target Labeling Protocol by Affymetrix (Santa Clara, CA) without ribosomal RNA reduction. Affymetrix GeneChip Human Gene 1.0 ST arrays were hybridized with 11 µg of labeled sense DNA, washed, stained, and scanned on an Affymetrix 7G Scanner according to the manufacturer's protocols.

2.3. Data processing and probe mapping

Data were extracted using the Affymetrix Expression Console software. Background correction, \log_2 transformation, quantile normalization, and median polish probeset summarization was performed using the Robust Multi-array Average (RMA) method [3] implemented in the RMAExpress software v1.0.5. The resulting dataset consisted of 28869 probesets. The BRB-ArrayTools v4.3.2 (developed by Dr. Richard Simon and BRB-ArrayTools Development Team) and Bioconductor R packages v2.12 [4] were used for probe filtering and annotation. Probesets were deemed as non-informative and excluded from further analysis under any of the following conditions: *P*-value of the log-ratio variation greater than 0.01, *i.e.* genes showing minimal variation across samples; 17th percentile of intensity less than 10, *i.e.* genes with the lowest acceptable expression level at most in three samples. Multiple probesets were reduced to one per gene symbol by using the most variable probe measured by interquartile range across arrays. After applying these stringent quality control and gene filtering criteria, we analyzed the expression changes over time of 6461 genes. Project was annotated with the Bioconductor annotation package *hugene10sttranscriptcluster.db* v8.0.1.

2.4. Statistical and bioinformatics analysis

Differentially expressed genes were sought combining two statistics implemented in the software MultiExperiment Viewer (MeV) v4.9 [5]. To identify genes varying significantly between the two conditions across time points, we used the Bayesian Estimation of Temporal Regulation (BETR) method [6], which is a linear random-effect modeling framework that takes into account correlations within samples between sampling times. Genes assigned a False Discovery Rate (FDR) < 0.1 were deemed significantly modulated. Then, to determine which genes were mainly influenced by the effect of Aminaphtone treatment *per se* (*i.e.* irrespective of the time response) and/or by the interaction effect of the two factors time and treatment, we applied a two-factor ANOVA to the gene list identified by BETR, given the balanced factorial design of the study. Genes were considered statistically significant if the *P*-values either for treatment and/or for interaction were < 0.05 . We finally performed post-hoc pairwise comparisons (2-tailed Student's *t*-test) to identify significant differences ($P < 0.05$) between treatment classes at any time points.

Unsupervised hierarchical clustering was performed using the algorithms implemented in BRB-ArrayTools, to visualize similarities and differences in gene expression profiles that could discriminate treatment classes and/or changes over time. \log_2 transformed, normalized gene expression values were median-centered, scaled, and clustered by Pearson's centered correlation and average linkage as distance metrics.

Functional analysis of significant genes identified by BETR was carried out by examining gene sets for differential expression between Aminaphtone treated and untreated samples. Gene sets were

derived from the Gene Ontology (GO) database (<http://www.geneontology.org>) [7], the Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/pathway.html>), and the curated gene sets of the Broad Institute Molecular Signature Database (MSigDB) [8]. LS/KS permutation tests were used to find gene sets with more genes differentially expressed among the phenotype classes than expected by chance. The threshold *P*-value was set at 0.005. Redundant GO terms were filtered out using the web-based tool REVIGO [9], allowing a similarity threshold of 0.5.

Acknowledgments

The authors gratefully acknowledge the excellent technical assistance of Elena Grovetti (Department of Pathophysiology and Transplantation, Università degli Studi di Milano). The work was entirely supported by internal funds from the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Transparency document. Supporting information

Transparency data associated with this article can be found in the online version at <http://dx.doi.org/10.1016/j.dib.2016.06.051>.

References

- [1] G. Salazar, C. Bellocchi, K. Todoerti, F. Saporiti, L. Piacentini, R. Scorza, G.I. Colombo, Gene expression profiling reveals novel protective effects of Aminaphtone on ECV304 endothelial cells, *Eur. J. Pharmacol.* 782 (2016) 59–69.
- [2] R. Edgar, M. Domrachev, A.E. Lash, Gene Expression Omnibus: NCBI gene expression and hybridization array data repository, *Nucleic Acids Res.* 30 (2002) 207–210.
- [3] R.A. Irizarry, B. Hobbs, F. Collin, Y.D. Beazer-Barclay, K.J. Antonellis, U. Scherf, T.P. Speed, Exploration, normalization, and summaries of high density oligonucleotide array probe level data, *Biostatistics* 4 (2003) 249–264.
- [4] R.C. Gentleman, V.J. Carey, D.M. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. Ellis, L. Gautier, Y. Ge, J. Gentry, K. Hornik, T. Hothorn, W. Huber, S. Iacus, R. Irizarry, F. Leisch, C. Li, M. Maechler, A.J. Rossini, G. Sawitzki, C. Smith, G. Smyth, L. Tierney, J.Y. Yang, J. Zhang, Bioconductor: open software development for computational biology and bioinformatics, *Genome Biol.* 5 (2004) R80.
- [5] A.I. Saeed, V. Sharov, J. White, J. Li, W. Liang, N. Bhagabati, J. Braisted, M. Klapa, T. Currier, M. Thiagarajan, A. Sturn, M. Snuffin, A. Rezantsev, D. Popov, A. Ryltsov, E. Kostukovich, I. Borisovsky, Z. Liu, A. Vinsavich, V. Trush, J. Quackenbush, TM4: a free, open-source system for microarray data management and analysis, *Biotechniques* 34 (2003) 374–378.
- [6] M.J. Aryee, J.A. Gutierrez-Pabello, I. Kramnik, T. Maiti, J. Quackenbush, An improved empirical bayes approach to estimating differential gene expression in microarray time-course data: BETR (Bayesian Estimation of Temporal Regulation), *BMC Bioinform.* 10 (2009) 409.
- [7] The Gene Ontology Consortium, Gene Ontology Consortium: going forward, *Nucleic Acids Res.*, 43, 2015, pp. D1049–D1056.
- [8] A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E. S. Lander, J.P. Mesirov, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, *Proc. Natl. Acad. Sci. USA* 102 (2005) 15545–15550.
- [9] F. Supek, M. Bosnjak, N. Skunca, T. Smuc, REVIGO summarizes and visualizes long lists of gene ontology terms, *PLoS One* 6 (2011) e21800.